|
|
||||||||
2-adrenoceptors mediate
nicotine-induced NOergic neurogenic dilation in porcine basilar
arteries
Department of Pharmacology, School of Medicine, Southern Illinois University, Springfield, Illinois 62794-9629
| |
ABSTRACT |
|---|
|
|
|---|
We
previously reported that nicotine-induced nitric oxide (NO)-mediated
cerebral neurogenic vasodilation was dependent on intact sympathetic
innervation. We hypothesized that nicotine acted on sympathetic nerve
terminals to release norepinephrine (NE), which then acted on
adrenoceptors located on the neighboring nitric oxidergic (NOergic)
nerve terminals to release NO, resulting in vasodilation. The
adrenoceptor subtype in mediating nicotine-induced vasodilation in
isolated porcine basilar arterial rings denuded of endothelium was
therefore examined pharmacologically and immunohistochemically. Results
from using an in vitro tissue bath technique indicated that propranolol
and preferential
2-adrenoceptor antagonists (ICI-118,551
and butoxamine), in a concentration-dependent manner, blocked the
relaxation induced by nicotine (100 µM) without affecting the
relaxation elicited by transmural nerve stimulation (TNS, 8 Hz). In
contrast, preferential
1-adrenoceptor antagonists
(atenolol and CGP-20712A) did not affect either nicotine- or
TNS-induced relaxation. Results of double-labeling studies indicated
that
2-adrenoceptor immunoreactivities and NADPH
diaphorase reactivities were colocalized in the same nerve fibers in
basilar and middle cerebral arteries. These findings suggest that NE,
which is released from sympathetic nerves upon application of nicotine,
acts on presynaptic
2-adrenoceptors located on the
NOergic nerve terminals to release NO, resulting in vasodilation. In
addition, nicotine-induced relaxation was enhanced by yohimbine, an
2-adrenoceptor antagonist, which, however, did not
affect the relaxation elicited by TNS. Prazosin, an
1-adrenoceptor antagonist, on the other hand, did not
have any effect on relaxation induced by either nicotine or TNS. The
predominant facilitatory effect of
2-adrenoceptors in releasing NO may be compromised by presynaptic
2-adrenoceptors.
nitric oxide; norepinephrine; porcine cerebral arteries
| |
INTRODUCTION |
|---|
|
|
|---|
MORPHOLOGICAL STUDIES have demonstrated that the close apposition between the adrenergic nerve terminal and the nonadrenergic or nitric oxide synthase (NOS) immunoreactive nerve terminal has frequently been found in large cerebral arteries at the base of the brain in several species (1, 11, 13). The axo-axonal distance between these different types of nerve terminals is substantially closer than the synaptic distance between the adventitial nerve terminals and the outermost layer of smooth muscle in the media (11, 13, 18). This morphological feature suggests that a functional axo-axonal interaction between nerve terminals is more likely to occur than that between the nerve and muscle. Thus transmitters released from one nerve terminal may modulate the release of transmitters from the neighboring nerve terminals and therefore the neurogenic vasomotor responses (5, 13).
We have recently demonstrated that nicotine-induced nitric oxide
(NO)-mediated neurogenic vasodilation is dependent on intact sympathetic, adrenergic innervation in porcine basilar arteries. This
is based on the observations that nicotine-induced NO-mediated cerebral
neurogenic vasodilation is abolished by guanethidine, a specific
sympathetic neuronal blocker, and by chemical denervation of
sympathetic nerves with 6-hydroxydopamine (6-OHDA), although these
treatments do not affect transmural nerve stimulation (TNS)-elicited NO-mediated neurogenic vasodilation in the same preparations. Furthermore, relaxation induced by exogenous norepinephrine (NE) in
porcine basilar arterial rings was blocked by
N
-nitro-L-arginine
(L-NNA; see Ref. 34). Accordingly, it was hypothesized that
nicotine acts on nicotinic receptors located on sympathetic nerve
terminals, resulting in release of NE or a related substance that then
diffused to act on its receptors located on the neighboring nitric
oxidergic (NOergic) nerve terminals to release NO and therefore induce
vasodilation (34). The exact nature of the receptors
located on NOergic nerves mediating nicotine-elicited NO release in
cerebral arteries has not been clarified. Our preliminary results
indicated that nicotine-induced neurogenic vasodilation in porcine
basilar arteries was blocked by propranolol, suggesting the possible
involvement of
-adrenoceptors in nicotine-induced neurogenic
vasodilation. This latter finding further supported the notion that NE
or a related substance was the mediator released from sympathetic nerve
terminals to cause NO release from NOergic nerves. The present study,
therefore, was designed to pharmacologically and immunohistochemically
characterize, in large cerebral arteries of the pig, the presynaptic
adrenoceptors presumably located on NOergic nerves, which mediate
nicotine-induced NOergic vasodilation.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
General procedure. Fresh heads of adult pigs (60-100 kg) of either sex were collected at local packing companies (Excel, Beardstown, IL and Y.T., Springfield, IL). The entire brain, with dura matter attached, was removed and placed in Krebs bicarbonate solution equilibrated with 95% O2-5% CO2 at room temperature. The composition of the Krebs solution was as follows (in mM): 122.0 NaCl, 5.16 KCl, 1.2 CaCl2, 1.22 MgSO4, 25.6 NaHCO3, 0.03 EDTA, 0.1 L-ascorbic acid, and 11.0 glucose (pH 7.4). Basilar and middle cerebral arteries were dissected and cleaned of surrounding tissue under a dissecting microscope.
In vitro tissue bath studies. The ring segment (4 mm long) was cannulated with a stainless-steel rod (30-gauge hemispherical section) and a short piece of platinum wire and was mounted horizontally in a plastic tissue bath containing 6 ml of Krebs bicarbonate solution. The platinum wire was bent into a U shape and anchored to a gate. The stainless steel rod was connected to a strain gauge (UC2; Gould) for isometric recording of changes in force, as described in our previous report (20). The temperature of the Krebs solution equilibrated with 95% O2-5% CO2 was maintained at 37°C. Tissues were equilibrated in the Krebs solution for an initial 30 min and then were mechanically stretched to a resting tension of 750 mg (34).
The basilar arterial ring segments were then precontracted with U-46619 (0.3-3 µM) to induce an active muscle tone of 0.5-0.75 g. TNS at 8 Hz and a single concentration of nicotine (100 µM) were applied to induce a relaxation. The arteries were then washed with prewarmed Krebs solution. A similar magnitude of active muscle tone was induced with U-46619 again, and TNS at 8 Hz was repeated (to serve as a control compared with the relaxation elicited by TNS before the wash). Experimental drugs were then administered, and TNS at 8 Hz and nicotine at the same concentration before the wash were repeated. To avoid possible development of tachyphylaxis upon repeated applications of nicotine (34), at least 90 min with six washes (every 15 min) were allowed before the next application of nicotine (34). Experimental drugs were added at least 30 min before TNS and application of nicotine. For TNS, tissues were electrically, transmurally stimulated with a pair of electrodes through which 100 biphasic square-wave pulses of 0.6 ms in duration and 200 mA in intensity were applied at various frequencies (17). Stimulation parameters were continuously monitored on a Tektronix oscilloscope. The neurogenic origin of this TNS-induced response was verified by its complete blockade by TTX (0.3 µM). At the end of each experiment, papaverine (100 µM) was added to induce a maximum relaxation. The magnitude of a vasodilator response was expressed as a percentage of the maximum response induced by papaverine (17). For examining effects of experimental drugs on relaxation induced by NE, concentration-response relations for NE were obtained by a cumulative technique in arteries without endothelial cells in the presence of active muscle tone induced by U-46619. After the arterial rings were washed with prewarmed Krebs solution, a similar magnitude of active muscle tone was again induced by U-46619. The experimental drugs were then added, and 15 min later concentration-response relations for NE were repeated. EC50 values were determined for each arterial ring. From these values, the geometric means EC50 with 95% confidence intervals (8) were calculated. The endothelial cells of all arterial ring segments were mechanically removed by a standard brief gentle rubbing of the intimal surface with a stainless steel rod having a diameter (25-30 gauge) equivalent to the lumen of the arteries (17). A complete removal of endothelial cells was verified by the lack of effect of L-NNA in increasing basal tone (19).Double-labeling immunohistochemistry.
Fresh porcine basilar and middle cerebral arteries obtained from local
slaughterhouses were dissected and placed into
periodate-parafomaldehyde-picric acid-formaldehyde-lysine
fixative (22) overnight at 4°C. After five washes in PBS
(pH 7.4), the arteries were permeabilized, and nonspecific sites were
blocked with 2.5% normal goat serum in 0.25% Triton X-100-PBS for 30 min at room temperature. The arteries were incubated with primary
antibodies (anti-rabbit
2-adrenocepter, 1:100; Affinity
BioReagents, Golden, CO) at 4°C for 24-48 h or at room
temperature for 4 h. After being rinsed with PBS (pH 8.2) three
times, the arteries were incubated with the secondary antibodies for
1 h at room temperature. The secondary antibodies were
FITC-labeled goat anti-rabbit IgG (1:40; Sigma Chemicals, St. Louis,
MO; see Ref. 33). After being rinsed with PBS (pH 8.2), each artery was
whole mounted with Vectashield mounting medium on Vectabond-coated slides (Vector Laboratories, Burlingame, CA). The labeled specimens were observed and photographed under a fluorescence microscope fitted
with proper filters (Olympus BX50 microscope). Negative controls were
obtained following the same procedure without the primary antibody
(33).
NADPHd histochemical staining. After fixation and incubation with specific antibodies for immunofluorescence labeling and photographing as described above, specimens were incubated in 0.1 M phosphate buffer (pH 8.0) containing 1 mg/ml of NADPH (reduced form), 0.1 mg/ml of nitro blue tetrazolium, and 0.2% Triton X-100 at 37°C for 1 h (4). The specimens were rinsed with PBS, mounted with Gel/Mount (Biomedia, Foster City, CA), and examined under a light microscope. For control of NADPHd activity, NADPH was omitted from the incubation medium. This resulted in elimination of NADPHd reaction product in perivascular nerves (4).
Drug used and statistical analysis. The following drugs were used: ±atenolol, butoxamine, CGP-20712A, and yohimbine (RBI, Natick, MA); atropine sulfate (Calbiochem, San Diego, CA); guanethidine sulfate and phentolamine (Ciba, Summit, NJ); dobutamine hydrochloride (Eli Lilly, Indianapolis, IN); prazosin hydrochloride (Pfizer, Brooklyn, NY); L-NNA, DL-propranolol hydrochloride, terbutaline, UTP, NADPH (reduced form), Triton X-100, and nitro blue tetrazolium (Sigma Chemical); ICI-118,551 hydrochloride (Imperial Chemical); and U-46619 (Upjohn, Kalamazoo, MI). All drugs were added directly to the tissue baths. The drug concentrations reported were the final concentrations in tissue bath.
Results were expressed as means ± SE. Statistical analysis was evaluated by Student's t-test for paired or unpaired samples as appropriate. The P < 0.05 level of probability was accepted as significant.| |
RESULTS |
|---|
|
|
|---|
Nicotine- and TNS-induced neurogenic vasodilation in porcine basilar arteries. In the presence of active muscle tone induced by U-46619 (0.3 µM), the basilar arteries without endothelial cells relaxed exclusively upon TNS at various frequencies (2, 4, and 8 Hz) and application of nicotine (1-100 µM). A complete removal of endothelial cells was verified by the lack of effect of L-NNA in increasing basal tone (19). Because TNS at 8 Hz and nicotine at 100 µM induced maximum relaxation, these parameters, which have previously been used by us and many others (17, 29, 34), were used in the subsequent studies. As reported previously by many investigators, neurogenic vasodilation induced by nicotine diminished upon repeated applications of this agonist with short time intervals (34). Accordingly, in the present study, a 90-min interval with six washes was allowed before repeating each application of nicotine. Three consecutive, reproducible relaxations induced by nicotine (100 µM) were obtained, which were not significantly different (34). Furthermore, the relaxation elicited by repeated TNS at 8 Hz, like other reports in the porcine cerebral arteries (17, 19), was reproducible and not different (34).
The relaxation induced by both nicotine (100 µM) and TNS (8 Hz) was significantly blocked by L-NNA (30 µM, n = 6), TTX (0.3 µM), and cold storage denervation for 7 days (data not shown). Furthermore, the relaxation induced by nicotine (100 µM) was diminished by guanethidine (1-10 µM) in a concentration-dependent manner. Blockade of nicotine-induced relaxation by guanethidine (1-10 µM) was fully recovered after the arteries were washed with fresh prewarmed Krebs solution (n = 5). On the other hand, guanethidine at similar concentrations never affected the TNS-elicited relaxation. These results were similar to those reported previously (34).Blockade of nicotine-induced neurogenic vasodilation by
-adrenoceptor antagonists but not by
-adrenoceptor antagonists.
In the presence of active muscle tone induced by U-46619 (0.3 µM) in
basilar arteries without endothelial cells, nicotine (100 µM)-induced
relaxation was significantly inhibited by propranolol (0.1-10
µM) in a concentration-dependent manner (Fig.
1, A and B). At 10 µM, propranolol abolished the nicotine-induced relaxation without any
effect on the TNS-elicited relaxation in the same preparations (Fig. 1,
A and B).
|
|
2-Adrenoceptor but not
1-adrenoceptor
antagonists blocked nicotine-induced neurogenic vasodilation.
In the presence of active muscle tone induced by U-46619 (0.3 µM) in
basilar arteries without endothelial cells, relaxation induced by
nicotine (100 µM) was diminished by ICI-118,551 and butoxamine
(selective
2-adrenoceptor antagonists) in a
concentration-dependent manner (0.01-10 µM; Fig. 2, A
and B). The nicotine-induced relaxation, however, was not
appreciably affected by
1-adrenoceptor antagonists such
as atenolol (0.01-10 µM, data not shown) and CGP-20712A
(0.01-10 µM, data not shown). At similar concentrations,
ICI-118,551, atenolol, butoxamine, and CGP-20712A did not affect the
TNS-elicited relaxation in the same preparations (data not shown).
Effect of ICI-118,551, atenolol, and CGP-20712A on NE-induced
relaxation in basilar arteries.
In the presence of phentolamine (1 µM) and active muscle tone induced
by U-46619 (0.3 µM), porcine basilar arteries without endothelial
cells relaxed upon application of NE in a concentration-dependent manner, a result similar to that reported previously (17).
The relaxation was blocked by ICI-118,551 (Fig.
3A), atenolol (Fig. 3B), and CGP-20712A (Fig. 3C), as indicated by
parallel shift of the concentration-response curves to the right.
CGP-20712A and atenolol appeared to be more potent than ICI-118,551.
Both CGP-20712A and atenolol at 0.1 µM already significantly shifted the concentration-response curve to the right, whereas ICI-118,551 at
same concentration was without any significant effect on NE-induced relaxation (Fig. 3). These
-adrenoceptor antagonists did not affect
relaxation induced by sodium nitroprusside (10 nM-10 mM) in arteries
denuded of endothelial cells (data not shown).
|
Immunocytochemistry.
Results from double-staining studies, i.e., single immunolabeling
followed by histochemical staining for NADPHd, which is a reliable
marker for neuronal NOS (33), indicated the presence of
2-adrenoceptor immunoreactive (Fig.
4A) and NADPHd reactive fine fibers and bundles (Fig. 4B) in the same whole-mount
basilar and middle cerebral arteries. In both arteries, almost all
NADPHd reactive fibers were coincident with
2-adrenoceptor immunoreactive fibers, but not all
2-adrenoceptor immunoreactive fibers were NADPHd
reactive. These NADPHd reactive and NADPHd negative fibers were
frequently found to run close to each other. It appeared that
2-adrenoceptor immunoreactive bundles were composed of
NADPHd reactive and NADPHd negative fibers. Therefore,
2-adrenoceptor immunoreactive bundles were frequently
found to be thicker than the corresponding NADPHd reactive bundles
(Fig. 4, A and B). For negative controls by
omitting primary antibodies, no immunoreactivities of
2-adrenoceptors were observed (data not shown).
|
| |
DISCUSSION |
|---|
|
|
|---|
The major finding of the present study was that nicotine-induced
neurogenic vasodilation in porcine basilar arteries was blocked by
preferential
2-adrenoceptor antagonists but not by
preferential
1-adrenoceptor antagonists. The
preferential
1-adrenoceptor antagonists, however, are
more potent than preferential
2-adrenoceptor antagonists
in blocking the postsynaptic
-adrenoceptor-mediated relaxation
induced by exogenously applied NE.
2-Adrenoceptor immunoreactivities and NADPHd reactivities were found to colocalize in
the same nerve fibers. Because NADPHd is a reliable marker for neuronal
NOS in porcine cerebral arteries (33), these results support our hypothesis that nicotine acts on presynaptic nicotinic receptors located on the adrenergic nerve terminals to release NE,
which then acts on the presynaptic
2-adrenoceptors
located on the neighboring NOergic nerves to cause release of NO and
therefore induces vasodilation (Fig. 5).
|
It is well established that nicotine releases NE by acting on nicotinic receptors located on sympathetic adrenergic nerve terminals (10, 27). Accordingly, nicotine was assumed to act directly on NOergic nerve terminals to release NO, resulting in NO-mediated cerebral neurogenic vasodilatation in many species (28). This assumption, however, was questioned, since our recent studies demonstrated for the first time that nicotine-induced NO-mediated relaxation in porcine cerebral arteries was dependent exclusively on intact sympathetic innervation (34). After a complete blockade of sympathetic transmission with guanethidine, or chemical denervation of sympathetic nerves with 6-OHDA, nicotine never induced a relaxation, although TNS-elicited NO-mediated relaxation in the same preparations remained unchanged. This latter finding was consistent with morphological observations that NOergic innervation remained intact while adrenergic nerves were completely denervated after treatment with 6-OHDA (34). These results indicate that in cerebral arteries nicotine does not act directly on NOergic nerves to release transmitter NO. Rather, nicotine acts on the nicotinic receptors located on sympathetic nerves to release NE, which then diffuses to the neighboring NOergic nerves and causes the release of NO from these nerves (34). The morphological evidence of close apposition (25 nm) between the adrenergic nerve terminals and the nonadrenergic nerve terminals for such axo-axonal interaction has been demonstrated to be a characteristic of cerebral vessel innervation in several species (1, 5, 11, 13).
Evidence that NE or a related catecholamine mediated nicotine-induced
NOergic vasodilation was supported by results of the present study that
nicotine-induced relaxation was blocked by propranolol (a nonspecific
-adrenoceptor antagonist). Further studies demonstrated that this
effect of nicotine was mediated specifically by presynaptic
2-adrenoceptors, since nicotine-induced relaxation was
blocked by preferential
2-adrenoceptor antagonists in a
concentration-dependent manner, but was not affected by
preferential
1-adrenoceptor antagonists. Both
preferential
1- and preferential
2-adrenoceptor antagonists, like propranolol, however,
significantly blocked postsynaptic
-adrenoceptor-mediated relaxation
induced by exogenous NE, a result consistent to those reported
previously (17, 23, 31,
32). Furthermore, propranolol and all preferential
1- and preferential
2-adrenoceptor
antagonists at concentrations examined in the present studies did not
affect TNS-elicited relaxation. This result is also consistent to those
reported previously (17, 31,
32), suggesting that blockade of nicotine-induced
relaxation by propranolol and
2-adrenoceptor antagonists
was not due to any possible local anesthetic effects of these agents at
the concentrations used. Together, these results suggest that
presynaptic
2-adrenoceptors on the NOergic nerves
mediate NE-induced NO release. Evidence has been presented that NE but
not dopamine or epinephrine is found in cerebral arteries, including
basilar and middle cerebral arteries from different species
(14, 17), further indicating that NE is the
most likely transmitter released by nicotine from sympathetic nerves to
cause release of NO from the neighboring NOergic nerves.
It should be noted that the porcine cerebral vascular smooth muscle,
unlike that of other species, contains mainly
-adrenoceptors, with
1-adrenoceptors as the predominant subtype in mediating NE-induced relaxation (23, 31,
32). This is further supported by results of the present
study that
1-adrenoceptor antagonists were more potent
than
2-adrenoceptor antagonists in blocking exogenous
NE-induced relaxation. In particular, CGP-20712A (a preferential
1-adrenoceptor antagonist) appears to be the most potent
-adrenoceptor antagonist in blocking relaxation induced by exogenous
NE. At 3 µM, CGP-20712A almost abolished the maximum relaxation
induced by NE but did not appreciably affect nicotine-induced neurogenic vasodilation. A similar result was found with a different
1-adrenoceptor antagonist (atenolol). On the other hand,
ICI-118,551 at 0.1 µM, which did not significantly affect the NE
concentration-relaxation response relationship (Fig. 3C),
significantly inhibited the nicotine-induced relaxation (Fig.
2C). These results indicate that neuronally released NE
induced by nicotine does not act on the postsynaptic
-adrenoceptors located on the smooth muscle cells to induce a relaxation. Rather, NE
acts as a presynaptic transmitter on presynaptic
2-adrenoceptors on the NOergic nerves to cause release
of NO and therefore vasodilation. The presence of presynaptic
2-adrenoceptors on the NOergic nerves is supported by
results from double-labeling studies that NADPHd reactive fibers
(markers for NOS-I fibers) are almost coincident with
2-adrenoceptor immunoreactive fibers in both basilar and middle cerebral arteries. However, not all
2-adrenoceptor imunoreactive fibers were NADPHd
reactive. This is an expected result, since
2-adrenoceptors are also found in association with other
types of nerves such as the noradrenergic neurons (24).
Similar results were found in isolated large cerebral arteries at the
base of the cat brain in which nicotine-induced vasodilation, which was
sensitive to L-NNA, was blocked by
2- but
not
1-adrenoceptor antagonists (our preliminary
data). In these cerebral arteries of the cat, postsynaptic
-adrenoceptors are predominant. Accordingly, exogenous NE has been
shown to induce a constriction exclusively (16,
22). These findings clearly indicate that nicotine-induced vasodilation in the cat cerebral arteries cannot be due to a direct effect of NE on the postsynaptic smooth muscle cells. Rather, NE as a
presynaptic transmitter acts on presynaptic
2-adrenoceptors located on NOergic nerves to cause
release of NO, which then induces vasodilation. This conclusion is
consistent with the reported biochemical findings that neurogenic
vasodilation in cerebral arteries from different species induced by
either TNS or nicotine is accompanied by an increase in cGMP but not
cAMP (9, 15, 29), suggesting
that the terminal transmitter acting on the smooth muscle to induce a
relaxation is NO (known to increase cGMP synthesis) or a related
substance but not NE (known to increase cAMP synthesis by its
-adrenoceptor activity).
In addition to that found in the cerebral arteries in the present
studies, the presence of
2-adrenoceptors on NOergic
nerves in the pulmonary and mesenteric arteries of the rat has been
speculated (21, 25). Adrenergic nerve
terminals in several preparations have been shown to contain
2-adrenoceptors, and these receptors mediate positive
feedback of NE release (24, 30). Blockade of
these presynaptic receptors by propranolol and other
-adrenoceptor antagonists only partially decreases the release of NE or NE-mediated vascular responses induced by nicotine or field electrical nerve stimulation (24, 30). This is different from
the present findings that nicotine-induced NE-mediated NOergic
vasodilation was abolished by propranolol and preferential
2-adrenoceptor antagonists. It is possible that the
presynaptic
2-adrenoceptors on NOergic nerve terminals
are more sensitive than those located on the adrenergic nerve terminals
to
-adrenoceptor antagonists.
It should be pointed out that NE is generally considered to be a weak
agonist for
2-adrenoceptors in the cardiovascular system (24). The possibility that other receptor subtypes such as
the
3-adrenoceptors and
4-adrenoceptors
(12) are involved in NE-mediated NO release remains to be
clarified. However, the complete blockade of nicotine-induced
relaxation by propranolol, which is not a ligand for
3-adrenoceptors (12), and the failure of
CGP-20712A, which is a
1- and
4-adrenoceptor antagonist (12), in blocking nicotine-induced relaxation render this possibility tenuous.
The involvement of the presynaptic
2-adrenoceptors in
mediating inhibition of NO release from NOergic nerves and NE release from adrenergic nerves in peripheral vascular preparations has been
reported (2). This appears to be true also in the porcine cerebral arteries, since nicotine-induced relaxation was potentiated by
yohimbine but not by prazosin. This is consistent with the present
hypothesis that increased NE release after blocking presynaptic
2-adrenoceptors on the sympathetic nerves by yohimbine
can result in increased NO release from the NOergic nerves and enhanced
vasodilation. The relative significance of
2-adrenoceptors located on adrenergic sympathetic nerve
terminals and NOergic nerve terminals in mediating nicotine-induced
NO-mediated relaxation remains to be determined. The presynaptic
2-adrenoceptors on NOergic nerve terminals, however, appear to be predominant in cerebral perivascular nerves, since NE-mediated nicotine-induced NOergic vasodilation in the absence of
yohimbine was demonstrated.
Results of our previous (34) and present studies indicate
that nicotine-induced NO-mediated neurogenic vasodilation in porcine basilar arteries is indirectly mediated by release of NE from sympathetic nerves. Nicotine does not act directly on NOergic nerves to
elicit an NO-mediated vasodilation (34). This effect of
nicotine in inducing NO-mediated neurogenic vasodilation is different
from that by TNS. The latter depolarizes the NOergic and sympathetic
nerve terminals simultaneously, resulting in NO-mediated relaxation,
although NE also is released upon TNS (our preliminary results). It is
possible that direct depolarization of the NOergic nerves by TNS at
various frequencies, resulting in NO release, is already at the maximum
enzyme stimulating capacity of each frequency. An additional
modulatory effect elicited by simultaneous release of NE from the
sympathetic nerves may be relatively small and therefore is not
detected. This may explain the well-established findings of the failure
of guanethidine (a blocker of sympathetic adrenergic transmission),
propranolol, preferential
2-adrenoceptor antagonists,
yohimbine, and other
-adrenoceptor antagonists in affecting
TNS-elicited NO-mediated neurogenic vasodilation in cerebral arteries
(Refs. 16, 17, 32, and 34 and the present results).
In summary, the present study demonstrated that nicotine-induced,
NO-mediated relaxation in porcine basilar arteries was inhibited by
blocking presynaptic
2-adrenoceptors and was enhanced by
blocking presynaptic
2-adrenoceptors. Although the
distribution of both presynaptic
2- and
2-adrenoceptors in adrenergic and NOergic nerves remains
to be determined, results from the present studies suggest that these
receptors are present on NOergic nerve terminals. Similar results were
found in the cat middle cerebral arteries and porcine internal carotid
arteries (our preliminary results). These findings together with those
from previous studies provide strong evidence that NE is the most
likely mediator, released from the adrenergic nerve terminals upon
application of nicotine, and acting predominantly on
2-adrenoceptors located on NOergic nerve terminals to
cause release of NO and the resulting cerebral vasodilation (Fig. 5).
NE therefore acts predominantly as a presynaptic transmitter.
Accordingly, it is possible that regional vasoconstriction induced by
electrical stimulation of the sympathetic nerves in vivo may be offset
by immediate vasodilation in the same regions due to NO release from
NOergic nerves. This finding may provide an explanation for the
reported observations that electrical stimulation of the sympathetic
nerves to cerebral circulation in normal experimental animals in
general results in a very weak effect or no response in cerebral
vascular tone and cerebral blood flow (3, 6, 7). This concept of presynaptic modulation of NOergic
nerves by sympathetic adrenergic nerves appears to be supported by
reports from some in vivo experimentation that the functional
consequence of neuronal NO and NE interaction may play a role in blood
pressure regulation (26).
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by National Heart, Lung, and Blood Institute Grants HL-27763 and HL-47574, by the American Heart Association/Illinois Heart Affiliate (9807871), and by the Southern Illinois University-Central Research Committee/Excellence in Academic Medicine.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: T. J. F. Lee, Dept. of Pharmacology, School of Medicine, Southern Illinois Univ., P O Box 19629, Springfield, IL 62794-9629 (E-mail: tlee{at}siumed.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Received 22 December 1999; accepted in final form 25 February 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Barroso, CP,
Edvinsson L,
Zhang W,
Cunha e Sa M,
Springall DR,
Polark JM,
and
Gulbenkian S.
Nitroxidergic innervation of guinea pig cerebral arteries.
J Auton Nerv Syst
58:
108-114,
1996[Web of Science][Medline].
2.
Boeckxstaens, GE,
De Man JG,
De Winter BY,
Moreels TG,
Herman AG,
and
Pelckmans PA.
Bioassay and pharmacological characterization of the nitrergic neurotransmitter.
Arch Int Pharmacodyn Ther
329:
11-26,
1995[Web of Science][Medline].
3.
Busija, DW,
and
Heistad DD.
Factors involved in the physiological regulation of the cerebral circulation.
Rev Physiol Biochem Pharmacol
101:
161-211,
1984[Web of Science][Medline].
4.
Chen, F-Y,
and
Lee TJ-F.
Arginine synthesis from citrulline in perivascular nerves of cerebral arteries.
J Pharmacol Exp Ther
273:
895-901,
1995
5.
Edvinsson, L,
Falck B,
and
Owman C.
Possibilities for a cholinergic action on smooth musculature and on sympathetic axons in brain vessels mediated by muscarinic and nicotinic receptors.
J Pharmacol Exp Ther
200:
117-126,
1977
6.
Edvinsson, L,
Mackenzie ET,
and
McCulloch J.
Cerebral Blood Flow and Metabolism. New York: Raven, 1993, p. 1-683.
7.
Faraci, FM,
Mayhan WG,
Werber AH,
and
Heistad DD.
Cerebral circulation: effects of sympathetic nerves and protective mechanisms during hypertension.
Circ Res
61:
II102-II106,
1987.
8.
Fleming, WW,
Westfall DP,
De la Lande IS,
and
Jellett LB.
Log-normal distribution of equiefective doses of norepinephrine and acetylcholine in several tissues.
J Pharmacol Exp Ther
181:
339-345,
1972
9.
Gonzalez, C,
Barroso C,
Martin C,
Gulbenkian S,
and
Estrada C.
Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries.
J Cereb Blood Flow Metab
17:
977-984,
1997[Web of Science][Medline].
10.
Haass, M,
Richardt G,
Brenn T,
Schomig E,
and
Schomig A.
Nicotine-induced release of noradrenaline and neuropeptide Y in guinea-pig heart: role of calcium channels and protein kinase C.
Naunyn-Schmiedeberg's Arch Pharmacol
344:
527-531,
1991[Web of Science][Medline].
11.
Iwayama, T,
Furness JB,
and
Burnstock G.
Dual adrenergic and cholinergic innervation of the cerebral arteries of the rat. An ultrastructural study.
Circ Res
26:
635-646,
1970
12.
Kaumann, AJ.
Four
-adrenoceptor subtypes in the mammalian heart.
Trends Pharmacol Sci
18:
70-76,
1997[Medline].
13.
Lee, TJF
Ultrastructural distribution of vasodilator and constrictor nerves in cat cerebral arteries.
Circ Res
49:
971-979,
1981
14.
Lee, TJF,
Chiueh M,
and
Adams M.
Synaptic transmission of vasoconstrictor nerves in the rabbit basilar artery.
Eur J Pharmacol
61:
55-70,
1980[Web of Science][Medline].
15.
Lee, TJF,
Fang YX,
and
GA
Nickols Cyclic nucleotides and cerebral neurogenic vasodilation.
In: Neurotransmission and Cerebrovascular Function, edited by Saylaz J,
and MacKenzie ET.. New York: Elsevier, 1989, p. 277-280.
16.
Lee, TJF,
Hume WR,
Su C,
and
Bevan JA.
Neurogenic vasodilation of cat cerebral arteries.
Circ Res
42:
535-542,
1978
17.
Lee, TJF,
Kinkead LR,
and
Sarwinski SJ.
Norepinephrine and acetylcholine transmitter mechanisms in large cerebral arteries of the pig.
J Cereb Blood Flow Metab
2:
439-450,
1982[Web of Science][Medline].
18.
Lee, TJF,
and
Saito A.
Altered cerebral vessel innervation in the spontaneously hypertensive rat.
Circ Res
55:
392-403,
1984
19.
Lee, TJF,
Sarwinski S,
Ishine T,
Lai C,
and
Chen FY.
Inhibition of cerebral neurogenic vasodilation by L-glutatmine and nitric oxide synthase inhibitors.
J Pharmacol Exp Ther
267:
353-358,
1996.
20.
Lee, TJF,
Su C,
and
Bevan JA.
Neurogenic sympathetic vasoconstriction of the rabbit basilar artery.
Circ Res
39:
120-126,
1976
21.
Marin, J,
and
Balfagon G.
Effect of clenbuterol on non-endothelial nitric oxide release in rat mesenteric arteries and the involvement of beta-adrenoceptors.
Br J Pharmacol
124:
473-478,
1998[Web of Science][Medline].
22.
Miao, FJP,
and
Lee TJF
Effects of billirubin on cerebral arterial tone in vitro.
J Cereb Blood Flow Metab
9:
666-674,
1989[Web of Science][Medline].
23.
Miyamoto, A,
Ito K,
and
Nishio A.
Characterization of beta-adrenoceptors in pig basilar artery from functional and radioligand binding studies.
Jpn J Pharmacol
61:
93-99,
1993[Medline].
24.
Nedergaard, OA,
and
Abrahamsen J.
Modulation of noradrenaline release by activation of presynaptic beta-adrenoceptors in the cardiovascular system.
Ann NY Acad Sci
604:
528-544,
1990[Web of Science][Medline].
25.
Priest, RM,
Hucks D,
and
Ward JP.
Noradrenaline, beta-adrenoceptor mediated vasorelaxation and nitric oxide in large and small pulmonary arteries of the rat.
Br J Pharmacol
122:
1375-1384,
1997[Web of Science][Medline].
26.
Sander, M,
and
Victor RG.
Neural mechanisms in nitric-oxide-deficient hypertension.
Curr Opin Nephrol Hypertens
8:
61-73,
1999[Web of Science][Medline].
27.
Su, C,
and
Bevan JA.
Blockade of the nicotine-induced norepinephrine release by cocaine, phenoxybenzamine and desipramine.
J Pharmacol Exp Ther
175:
533-540,
1970
28.
Toda, N,
Ayajiki K,
and
Okamura T.
Inhibition of nitroxidergic nerve function by neurogenic acetylcholine in monkey cerebral arteries.
J Physiol (Lond)
498:
453-461,
1997
29.
Toda, N,
and
Okamura T.
Cerebral vasodilators.
Jpn J Pharmacol
76:
349-367,
1998[Medline].
30.
Tsuji, T,
Su C,
and
Lee TJF
Enhanced presynaptic beta-2 adrenoceptor-mediated facilitation of the pressor responses in the prehypertensive SHR.
J Cardiovasc Pharmacol
14:
737-746,
1989[Web of Science][Medline].
31.
Wang, JY,
and
Lee TJF
Beta-receptor-mediated vasodilation in cerebral arteries of the pig.
Acta Physiol Scand
127:
41-44,
1986.
32.
Winquist, RJ,
Webb RC,
and
Bohr DF.
Relaxation to transmural nerve stimulation and exogenously added norepinephrine in porcine cerebral vessels: a study utilizing cerebrovascular intrinsic tone.
Circ Res
51:
769-776,
1982
33.
Yu, JG,
Kimura T,
Chang XF,
and
Lee TJ-F.
Segregation of VIPergic-nitric oxidergic and cholinergic-nitric oxidergic innervation in porcine middle cerebral arteries.
Brain Res
801:
78-87,
1998[Web of Science][Medline].
34.
Zhang, W,
Edvinsson L,
and
Lee TJF
Mechanism of nicotine-induced neurogenic vasodilation in the porcine basilar artery.
J Pharmacol Exp Ther
284:
790-797,
1998[Abstract].
This article has been cited by other articles:
![]() |
H. Kawasaki, S. Eguchi, S. Miyashita, S. Chan, K. Hirai, N. Hobara, A. Yokomizo, H. Fujiwara, Y. Zamami, T. Koyama, et al. Proton Acts as a Neurotransmitter for Nicotine-Induced Adrenergic and Calcitonin Gene-Related Peptide-Containing Nerve-Mediated Vasodilation in the Rat Mesenteric Artery J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 745 - 755. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mozayan and T. J. F. Lee Statins prevent cholinesterase inhibitor blockade of sympathetic {alpha}7-nAChR-mediated currents in rat superior cervical ganglion neurons Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1737 - H1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. T. Hare, J. M. A. Worrall, A. J. Baker, E. Liu, N. Sikich, and C. D. Mazer {beta}2 Adrenergic antagonist inhibits cerebral cortical oxygen delivery after severe haemodilution in rats Br. J. Anaesth., November 1, 2006; 97(5): 617 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Vanterpool, E. A. Vanterpool, W. J. Pearce, and J. N. Buchholz Advancing age alters the expression of the ryanodine receptor 3 isoform in adult rat superior cervical ganglia J Appl Physiol, August 1, 2006; 101(2): 392 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Long, M.-F. Chen, S. J. Sarwinski, P.-Y. Chen, M. Si, B. J. Hoffer, M. S. Evans, and T. J. F. Lee Monoamine uptake inhibitors block {alpha}7-nAChR-mediated cerebral nitrergic neurogenic vasodilation Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H202 - H209. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Jennings, B. R. S. Broughton, and J. A. Donald Nitric oxide control of the dorsal aorta and the intestinal vein of the Australian short-finned eel Anguilla australis J. Exp. Biol., March 15, 2004; 207(8): 1295 - 1303. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Mbaku, L. Zhang, W. J. Pearce, S. P. Duckles, and J. Buchholz Chronic hypoxia alters the function of NOS nerves in cerebral arteries of near-term fetal and adult sheep J Appl Physiol, February 1, 2003; 94(2): 724 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-L. Si and T. J. F. Lee Presynaptic alpha 7-Nicotinic Acetylcholine Receptors Mediate Nicotine-Induced Nitric Oxidergic Neurogenic Vasodilation in Porcine Basilar Arteries J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 122 - 128. [Abstract] [Full Text] |
||||
![]() |
S. Guimaraes and D. Moura Vascular Adrenoceptors: An Update Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |